PANCREATIC CANCER TREATMENT PATHWAYS

Pancreatic cancer is rarely the same case twice. A tumour in the head of the pancreas behaves differently from one in the body or tail. Vascular involvement, lymph node spread, distant metastasis, biomarker findings, and the patient's nutritional status all influence what is realistic. Many patients are told only one option exists when, in fact, sequencing, neoadjuvant therapy, biomarker testing, and trial access could reasonably change the plan. Structured review by an experienced multidisciplinary team is one of the most valuable steps a family can take after diagnosis.

Resectable disease (Stage I and selected Stage II) When the tumour is confined to the pancreas without major vascular involvement, surgery offers the strongest chance of long-term control. The procedure depends on tumour location: a pancreaticoduodenectomy (Whipple) for head tumours, distal pancreatectomy with splenectomy for body and tail tumours, and total pancreatectomy in selected cases. Surgery is almost always followed by adjuvant chemotherapy — typically modified FOLFIRINOX in fit patients or gemcitabine-based regimens otherwise — to reduce recurrence risk. In some centres, neoadjuvant chemotherapy before surgery is preferred even for clearly resectable tumours. Borderline resectable disease When the tumour touches or partially encases major vessels, upfront surgery rarely achieves clean margins. The standard approach is neoadjuvant chemotherapy, often with FOLFIRINOX or gemcitabine plus nab-paclitaxel, sometimes followed by chemoradiation or stereotactic body radiation therapy (SBRT). Patients are then reassessed for surgery. This pathway requires careful coordination between medical oncology, radiation oncology, and surgical teams. Locally advanced disease (Stage III) Locally advanced tumours involve major vessels too extensively for upfront surgery. Treatment usually starts with systemic chemotherapy for four to six months. If the disease responds well, chemoradiation, SBRT, or surgical exploration may follow. A subset of patients become candidates for surgery; others continue on maintenance therapy. Irreversible electroporation (IRE), HIFU, and selected ablative approaches are also available in some international centres for non-resectable local disease. Metastatic disease (Stage IV) For metastatic pancreatic cancer, systemic therapy is the foundation. First-line options usually include FOLFIRINOX or gemcitabine plus nab-paclitaxel, chosen based on fitness, organ function, and goals of care. Second-line options include NALIRIFOX, liposomal irinotecan with 5-FU, or gemcitabine-based regimens depending on prior therapy. For patients with actionable findings, targeted and immune therapies enter the conversation: PARP inhibitors for germline BRCA1/2 or PALB2 mutations, KRAS G12C inhibitors in eligible patients, NTRK or NRG1 fusion-targeted agents in rare cases, and immune checkpoint inhibitors for MSI-H or dMMR tumours. Clinical trials remain an important option throughout.

Pancreatic cancer was once treated almost identically across all patients. That has changed. Comprehensive genomic profiling can now identify actionable findings in roughly one in four to one in three patients, opening up therapies that would otherwise be missed. Germline testing is recommended for nearly all patients with pancreatic adenocarcinoma, since BRCA1/2, PALB2, ATM, and Lynch syndrome mutations have direct treatment implications and family-screening relevance. CancerFax routinely helps patients access reliable NGS panels and germline testing in India, China, Germany, and other countries when local options are limited.

Case review — diagnosis, staging, biomarkers, and prior treatment are reviewed to identify whether the current pathway is optimal or whether alternatives deserve consideration. Second opinion coordination — reports are shared with experienced pancreatic cancer specialists and multidisciplinary tumour boards in India, China, Germany, the United States, and other regions. Biomarker and NGS access — if molecular testing has not been done, CancerFax helps arrange reliable panels and interpret findings against current treatment options. Treatment and trial matching — actionable findings are mapped to approved therapies, biosimilars, and clinical trials, including KRAS, BRCA, NTRK, and immunotherapy-relevant studies. Logistics and follow-up — admission, travel, interpreter support, and continuity of care after returning home are coordinated through a single point of contact.

Frequently Asked Questions

Answers to common questions from patients and families.